Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493019 | PMC |
| http://dx.doi.org/10.5115/acb.21.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MR-Guided PET Reconstruction: A Potential Advancement for Patients With Epilepsy.
Clin Nucl Med
December 2024
GE HealthCare, Waukesha, WI.
We report a case of a 33-year-old man with epilepsy and equivocal EEG, MRI signs of mesiotemporal sclerosis, and nondiagnostic standard FDG-PET imaging. The patient underwent repeat FDG-PET/MRI to clarify the sidedness of the epileptogenic focus and to confirm the suspected MTS. The standard PET reconstruction using block sequential regularized expectation maximization failed to provide evidence of a clear epileptogenic focus.
View Article and Find Full Text PDFTranexamic Acid in Rhytidectomy: A Split-Face Multi-Institutional Study.
Facial Plast Surg Aesthet Med
November 2024
Hamilton Facial Plastic Surgery, Greenwood, Indiana, USA.
Tranexamic acid (TXA) has the ability to reduce intraoperative bleeding and facilitate hemostasis in addition to its anti-inflammatory properties that can potentially aid in recovery among patients who underwent rhytidectomy. To compare postoperative ecchymosis in patients who underwent rhytidectomy with TXA added to the tumescent anesthetic. A multi-institutional, single-blind study was performed on patients who underwent rhytidectomy.
View Article and Find Full Text PDFFirst-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.
JAMA Oncol
November 2024
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Article Synopsis
- Patients with colorectal cancer and liver-only metastases showed improved outcomes when treated with FOLFOXIRI and bevacizumab compared to FOLFIRI and bevacizumab or with panitumumab, especially regarding progression-free survival and resection rates.
- The CAIRO5 trial involved 530 patients with initially unresectable liver metastases from colorectal cancer, evaluated across numerous centers in the Netherlands and Belgium, focusing on different treatment combinations based on tumor genetics.
- While more effective responses were observed with certain treatments, there was an increase in toxic side effects, particularly in specific genetic tumor variants like RAS/BRAFV600E.
Sidedness and Molecular Pattern in Defining the Risk of Lymph Node Metastasis in Nonmetastatic Colorectal Cancer: Single-Center Retrospective Study.
Cancers (Basel)
September 2024
Department of Medical Surgical Science and Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, 00198 Rome, Italy.
: Lymphadenectomy plays a central role in the treatment of localized colon cancer. While in left colon cancer the D3 lymphadenectomy/CME is considered the standard of care, lymphatic stations to be removed in right colon cancer are still a matter of discussion. The individuation of LNM risk factors could help in choosing the lymphadenectomy in right-sided tumors.
View Article and Find Full Text PDFAssessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.
J Clin Oncol
December 2024
ARCAD Foundation, Paris, France.
Purpose: The adjuvant treatment for stage III colon cancer (CC) is chemotherapy combining fluoropyrimidine (FP) and oxaliplatin (OX). FP regimen plus OX (FPOX) may benefit in high-risk stage II CC. We performed a pooled analysis of pivotal MOSAIC and C-07 studies evaluating FPOX for the treatment of high-risk stage II CC according to prognostic factors, number of high-risk factors, and current clinicopathologic risk classification on the basis of T stage, tumor perforation, and number of lymph nodes examined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!